Iliad Research

ILiAD Biotechnologies is a clinical-stage biotechnology company focused on developing next-generation vaccines for respiratory diseases, specifically targeting Bordetella pertussis (whooping cough). The company's lead candidate, BPZE1, is a live-attenuated, intranasal vaccine designed to provide superior mucosal immunity and prevent both disease and transmission, addressing the shortcomings of current acellular vaccines. ILiAD is also exploring the use of its BPZE1 platform as a vector for other respiratory antigens, such as those for Respiratory Syncytial Virus (RSV). The company's mission is to reduce the global burden of pertussis and other respiratory infections through innovative vaccine technology. Based on research from the Institut Pasteur de Lille, the platform aims to provide long-lasting protection and block colonization in the upper respiratory tract.